BAE Seminar: Commercializing the CRISPR craze: lessons in managing innovation and disruptive technologies
November 28, 2023 3:00PM - 12:00AM
https://msu.zoom.us/j/97361984173
“Commercializing the CRISPR craze: lessons in managing innovation and disruptive technologies.”
Tuesday, November 28, 2023 at 3PM EST
Zoom Only: https://msu.zoom.us/j/97361984173
Meeting ID: 973 6198 4173
Abstract: The advent of CRISPR-based technologies has revolutionized our ability to manipulate the genetic content of organisms across the tree of life, and democratized genome editing across the globe. Repurposed from obscure adaptive immune systems in bacteria, CRISPR molecular machines have been broadly deployed in academia and industry in the past 10 years, to manipulate the genomes of organisms relevant to medicine, biotechnology, and agriculture. We now have access to a portable CRISPR toolbox enabling flexible editing from a single nucleotide to large scale genome manipulation in organisms that span minimalistic viruses to large trees and their corresponding genome range and complexities. I will look back on the historical milestones that have paved the way for the CRISPR era, and discuss the diverse applications that have impacted and continue to shape the fields of Medicine, Ag, Food, and Biotechnology. I will discuss the impacts this transformative field has had on science and society, and business implications of this disruptive technology. In particular, I will discuss technology transfer from academia to industry and illustrate challenges and opportunities that have and continue to shape CRISPR start-up companies and their strategic partners. In many ways, the CRISPR craze is a compelling template for the commercialization of a disruptive and innovative technology across industries, business segments, and company types, and I will discuss how successful companies and academic startups can assemble and exploit ingredients for innovation-fueled success. I will also contextualize CRISPR commercialization with regards to regulatory frameworks, intellectual property pursuit, public engagement, consumer acceptance, and geopolitical issues fueling and sometimes hampering commercialization efforts.
Bio: Rodolphe Barrangou Ph.D. is the T. R. Klaenhammer Distinguished Professor at North Carolina State University. Barrangou is focusing on the characterization of CRISPR-Cas systems, and their applications in bacteria. The CRISPRlab has published numerous studies on the various applications of CRISPR-Cas systems, and illustrated their use for the study and development of probiotics, including for genotyping, phage resistance, screening, genome editing and antimicrobials, to understand and enhance health-promoting functions of interest. The work has spanned basic scientific to understand and decipher the genomics of lactic acid bacteria, as well as developing novel technologies and applying them to develop and formulate next-generation bacterial strains. Rodolphe spent 9 years in R&D and M&A at Danisco and DuPont, and has been at NC State since 2013. For his CRISPR work, Rodolphe received several international awards, including the 2016 Canada Gairdner International Award, the 2016 Harvard Medical School Warren Alpert Prize, the 2017 NAS Award in Molecular Biology and the 2018 NAS Prize in Food and Agriculture Sciences. He has been elected into the National Academy of Sciences, the National Academy of Engineering, the National Academy of Inventors, the American Academy of Microbiology and the National Inventors Hall of Fame. Dr. Barrangou earned a BS in Biological Sciences from Rene Descartes University in Paris, France, a MS in Biological Engineering from the University of Technology in Compiegne, France, a MS in Food Science from NC State, a PhD in Genomics from NC State and a MBA from the University of Wisconsin-Madison. Dr. Barrangou is also the former Chairman of the Board of Caribou Biosciences (NASDAQ CRBU), a co-founder of Intellia Therapeutics (NASDAQ NTLA), Locus Biosciences, TreeCo, Ancilia Biosciences and CRISPR Biotechnologies, an advisor to Inari Ag, Invaio, Provaxus and Felix Biotech, and the Editor in Chief of the CRISPR Journal.
Print
Email